Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a dose dense administration of Rituximab in
newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate
following this treatment.
Correlative studies will be performed as outlined in the appendices.
Quality of Life will be measured using the KIT as outlined in the protocol.